Demand for DNA is increasing in scale and complexity with the rapid advancement of DNA enabled therapeutics including cell and gene therapies and DNA vaccines. Plasmid DNA manufacturing is unable to adequately meet this demand, with its major limitations including cost, time, regulatory concern with antibiotic resistance genes, and difficulty amplifying DNA with complex secondary structures or repetitive sequences. Touchlight has developed an enzymatic means of DNA amplification that addresses all major limitations of plasmid DNA and meets the demands of the DNA revolution. Touchlight's in vitro dual enzyme process can amplify any circular template to commercial scale and quality. Our doggybone™ or dbDNA™ is a linear covalently closed, minimal DNA construct that contains no bacterial sequences. Our ambition is for dbDNA™ to underpin the development and commercialisation of the next generation of DNA products. Discover more about our technology and our business at Touchlight.com.
Company Growth (employees)